TipRanks
Advertisement
Advertisement

MX:RARE Stock Latest News

Ultragenyx Monetizes FDA Priority Review Voucher Asset
Company AnnouncementsUltragenyx Monetizes FDA Priority Review Voucher Asset
24h ago
8K
RARE
Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M
PremiumThe Fly
Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M
1d ago
RARE
Ultragenyx: FDA Gene Therapy Progress and Upcoming Pivotal Readouts Support Buy Rating with Unchanged $25 Price Target
PremiumRatings
Ultragenyx: FDA Gene Therapy Progress and Upcoming Pivotal Readouts Support Buy Rating with Unchanged $25 Price Target
13d ago
RARE
Ultragenyx call volume above normal and directionally bullish
PremiumThe Fly
Ultragenyx call volume above normal and directionally bullish
15d ago
RARE
Ultragenyx price target raised to $18 from $16 at Evercore ISI
PremiumThe Fly
Ultragenyx price target raised to $18 from $16 at Evercore ISI
17d ago
RARE
Ultragenyx price target raised to $35 from $32 at Barclays
PremiumThe FlyUltragenyx price target raised to $35 from $32 at Barclays
17d ago
RARE
Ultragenyx price target raised to $20 from $18 at Morgan Stanley
Premium
The Fly
Ultragenyx price target raised to $20 from $18 at Morgan Stanley
20d ago
RARE
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
Premium
The Fly
Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111
20d ago
ABEO
RARE
Ultragenyx price target raised to $39 from $37 at Canaccord
PremiumThe Fly
Ultragenyx price target raised to $39 from $37 at Canaccord
20d ago
RARE
Ultragenyx price target raised to $39 from $33 at Cantor Fitzgerald
PremiumThe Fly
Ultragenyx price target raised to $39 from $33 at Cantor Fitzgerald
20d ago
RARE
Ultragenyx price target raised to $32 from $31 at Citi
PremiumThe Fly
Ultragenyx price target raised to $32 from $31 at Citi
20d ago
RARE
Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts
PremiumRatings
Ultragenyx: Fayuvi Approval and Stronger Balance Sheet Support Hold Rating Amid Limited Near‑Term Catalysts
20d ago
RARE
Ultragenyx wins FDA approval for FAYUVI gene therapy
PremiumCompany AnnouncementsUltragenyx wins FDA approval for FAYUVI gene therapy
21d ago
8K
RARE
Ultragenyx confirms FDA approval of Fayuvi
Premium
The Fly
Ultragenyx confirms FDA approval of Fayuvi
21d ago
RARE
FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A
Premium
The Fly
FDA approves Ultragenyx gene therapy for Sanfilippo syndrome type A
21d ago
RARE
Ultragenyx call volume above normal and directionally bullish
PremiumThe Fly
Ultragenyx call volume above normal and directionally bullish
22d ago
RARE
Ultragenyx treatment of GNE myopathy granted orphan designation
PremiumThe Fly
Ultragenyx treatment of GNE myopathy granted orphan designation
24d ago
RARE
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
PremiumThe Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
28d ago
GS
MS
Ultragenyx price target lowered to $32 from $43 at Barclays
PremiumThe Fly
Ultragenyx price target lowered to $32 from $43 at Barclays
1M ago
RARE
Ultragenyx downgraded at Morgan Stanley after Angelman study fails
PremiumThe FlyUltragenyx downgraded at Morgan Stanley after Angelman study fails
1M ago
RARE
Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley
Premium
The Fly
Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley
1M ago
RARE
Ultragenyx falls -44.0%
Premium
The Fly
Ultragenyx falls -44.0%
1M ago
RARE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >